INTRODUCTION
One of the most impactful discoveries in melanoma was the identification of missense mutations in the BRAF gene. Approximately 95% of these mutations result in substitutions for valine at position 600 of the BRAF protein (BRAF V600 ), most commonly with glutamic acid (BRAF V600E ). 1 These mutations markedly activate the RAS-RAF-mitogen-activated protein kinase signaling pathway. In addition to improving the understanding of the molecular pathogenesis of melanoma, this discovery led to the development of highly effective targeted therapies for patients with BRAF V600 mutations, including the mutant-selective BRAF inhibitors vemurafenib and dabrafenib and the mitogen-activated protein kinase kinase (MEK) inhibitors trametinib and cobimetinib. Together, these developments strongly support investigating the significance of other somatic mutations in this disease to identify additional personalized therapeutic strategies.
Recently, we reported the results of a clinical next-generation sequencing (NGS) panel that encompassed commonly mutated regions in 46 genes in a large cohort of advanced melanoma patients. 2 The most common mutations detected in the cutaneous melanoma patients were BRAF V600 (41%), NRAS (22%), TP53 (17%), and BRAF Non-V600 (7%). Previous studies that have examined the clinical and pathological features correlating with BRAF V600 and NRAS mutations have identified a number of significant associations. 3 However, very little is known about features of melanomas that are associated with TP53 mutations, which correlate with poor clinical outcomes for patients with head and neck cancer 4 and hematologic malignancies. 5 Preclinical studies support that BRAF Non-V600 mutations are a potential therapeutic target, 6 and there are ongoing clinical trials seeking to determine the efficacy of trametinib (a MEK inhibitor) in melanoma patients with these mutations (NCT02296112). However, little is known at this time about the clinical features or outcomes associated with BRAF Non-V600 mutations in melanoma patients.
We have performed a retrospective analysis of a large, single-institution cohort of advanced cutaneous melanoma patients with clinical NGS testing results, which encompassed regions of prevalent hotspot mutations in 50 genes. We have examined this cohort to identify clinical and pathological features that are associated with the presence of TP53 and BRAF Non-V600 mutations to improve our understanding of their significance in this disease.
MATERIALS AND METHODS

Patient Selection and Clinical Data Collection
Under an institutional review board-approved protocol, the results of clinically indicated molecular testing performed at The University of Texas MD Anderson Cancer Center from April 2012 to November 2014 for patients with non-acral cutaneous melanoma were reviewed. Information was collected about patient demographics, primary tumor characteristics, treatments received, and overall survival (OS).
Mutation Testing
Molecular testing by a pan-cancer NGS panel of hotspot regions in 50 genes (Supporting Table 1 [see online supporting information]) was performed on DNA extracted from formalin-fixed, paraffin-embedded tissues from melanoma primary tumors or metastases with the AmpliSeq sequencing panel (CMS50; Life Technologies) as previously described. 2, 7 Among detected mutations in the panel, TP53 mutations were further classified on the basis of physicochemical or functional consequences, including truncating mutations, missense mutations, DNA-binding domain mutations, and ultraviolet signature mutations. Truncating mutations are mutations leading to a stop codon, frame shift, or splice defect. 8 Missense mutations are characterized by an amino acid change that results in a dominant-negative or a gain of function.
9 DNA-binding domain mutations are mutations in codons 102 to 292 that induce inactivation of TP53 by eliminating DNA-binding contacts or altering the structural stability of the core domain. 9 Missense mutations are further stratified as high (75) and low risk (<75) by an evolutionary action score system (http://mammoth.bcm. tmc.edu/EAp53/) to predict highly deleterious TP53 functions; this was validated for head and neck squamous cell carcinoma. 10 To verify the coverage of the CMS50 panel, potential hotspot mutations in cutaneous melanoma data from The Tumor Genome Atlas (TCGA) 11 were identified, as previously described, with the HotSpotter method, which allows rapid and easy visualization of mutation data sets and identification of potential gene mutation hotspot sites and/or regions. 12 The potential hotspot mutations identified by the HotSpotter analysis were compared with the CMS50 panel.
Statistical Methods
The association between continuous parameters and the mutational status was assessed with an analysis of variance. Fisher's exact test was used to assess the association between categorical variables (primary tumor site, ulceration, and elevated lactate dehydrogenase [LDH] ) and the mutational status. Wilcoxon rank-sum tests were used to assess the association between continuous and ordinal variables (age, Breslow thickness, and M1 stage) and the mutational status. The Kaplan-Meier method was used to estimate the distribution of OS, and log-rank testing was performed to determine the significance of observed differences. All statistical analyses were performed with R (version 3.1.1). All statistical tests used a significance level of 5%. No adjustments for multiple testing were performed.
RESULTS
Patients Demographics and Mutation Frequency
A total of 926 patients with non-acral cutaneous primary melanoma and clinical NGS testing results from the CMS50 panel were identified ( Table 1 ). The median age of the patients was 56 years (range, 12-94 y), and 67.4% were male. Superficial spreading melanoma was the most common melanoma subtype, and the trunk was the most common primary tumor site. Five hundred thirty-one patients (57.3%) were diagnosed with stage IV disease.
A BRAF V600 mutation was detected in 398 patients (43.0%), an NRAS mutation was detected in 195 (21.1%), a TP53 mutation was detected in 180 (19.4%), and a BRAF Non-V600 mutation was detected in 60 (6.5%; Table 2 ). The prevalence of the specific BRAF V600 , NRAS, TP53, and BRAF Non-V600 substitutions detected in the cohort is presented in Supporting Tables 2 to 5 (see online supporting information). TP53 mutations were detected in 11.3% of melanomas with a BRAF V600 mutation, in 19.4% of tumors with an NRAS mutation, and in 28.9% of tumors without a BRAF V600 or NRAS mutation (Supporting Table 6 and Supporting Fig. 1A [see online supporting information]). A BRAF Non-V600 mutation was detected in 0.5% of melanomas with a BRAF V600 mutation, in 4.1% of tumors with an NRAS mutation, and in 14.9% of tumors without a BRAF V600 or NRAS mutation (Supporting Table 7 An analysis of the full patient cohort showed that the presence of a TP53 mutation that was detectable by the clinical CMS50 panel was associated with increased age at diagnosis (median, 58 vs 56 years; P 5 .019; Table 3 ). TP53 mutations were also significantly associated with the primary tumor site (P 5 .0001) because they were more common in tumors of the head and neck (27.4%) than the trunk (15.9%) or extremities (14.7%). TP53 mutations were not significantly associated with the primary tumor thickness or ulceration status. Among the 531 patients who had developed stage IV disease, there was no significant association between the TP53 mutation status and the M stage or serum LDH level at the diagnosis of stage IV disease. Similar analyses were performed to assess the characteristics associated with TP53 mutations separately in melanomas with a concurrent BRAF V600 mutation, in melanomas with a concurrent NRAS mutation, and in melanomas without a BRAF V600 or NRAS mutation (Supporting Table 6 [see online supporting information]). There were no significant associations with the TP53 mutation status in tumors with BRAF V600 mutations or with NRAS mutations. Significant associations with the age at diagnosis (P 5 .001) and the primary tumor site (P 5 .009) were observed in tumors without a BRAF V600 or NRAS mutation.
TP53 Mutations and OS From Stage IV
To avoid a bias due to the inclusion of patients with unusually long survival intervals before molecular testing, the analysis of outcomes after the stage IV diagnosis was limited to patients with clinical NGS testing performed within 12 months of the diagnosis (n 5 417). The prevalence of TP53 mutations detected by the CMS50 panel among these patients was 21.1%. Patients with a TP53 mutation had longer OS from the diagnosis of stage IV in the univariate analysis (median, 18.8 vs 15.3 months; P 5 .039; Fig. 1A ). OS from stage IV was very similar for patients with a BRAF V600 mutation with or without a 
TP53 mutation (median, 17.5 vs 16.9 months; P 5 .89; Supporting Fig To further evaluate the prognostic significance of TP53 mutations, outcomes with US Food and Drug Administration (FDA)-approved therapies for the stage IV cohort were reviewed. A total of 146 patients with clinical NGS testing performed within 12 months of the stage IV diagnosis were treated with frontline ipilimumab; they included 35 patients with a TP53 mutation. No significant correlation was observed between the TP53 mutation status and OS from the start of ipilimumab treatment in the full cohort (median, 11.1 months for the TP53-mutant group vs 13.9 months for the group with no TP53 mutation detected; P 5 .46; Fig. 1B ). There was also no significant association with OS from the start of ipilimumab by the TP53 mutation status among the cohorts defined by the concurrent BRAF V600 and NRAS mutation status (Supporting Among the patients with a BRAF V600 mutation, 64 patients in the cohort were treated with an FDA-approved BRAF inhibitor as first-line therapy for stage IV disease (Supporting Table 8 [see online supporting information]). The objective response rate (ORR) did not differ significantly between the patients with (n 5 9; ORR, 55.6%) and without a TP53 mutation (n 5 55; ORR, 47.3%; P 5 .7). The TP53 mutation status was also not significantly associated with progression-free survival (PFS; P 5 .42) or OS (P 5 .49) with BRAF inhibitor treatment (Supporting Fig. 4A ,B [see online supporting information]).
The outcomes associated with TP53 mutations were further characterized by an analysis of the nature of the observed mutations in the stage IV patients because different types of mutations in TP53 may have different prognostic significance. In agreement with the strong association of non-acral cutaneous melanoma with ultraviolet radiation (UVR) exposure, 58.2% of the detected TP53 mutations in the cohort were substitutions that are associated with UVR-related DNA damage. This rate is similar to the rate observed in the cutaneous melanoma TCGA cohort (45.3%). 11 Patients with UVR-related (n 5 55; median OS, 17.5 months) and non-UVRrelated TP53 mutations (n 5 31; median OS, 24.0 months) had trends for improved OS from stage IV in comparison with patients without a detectable TP53 mutation (median OS, 15.3 months), but these differences did not reach statistical significance (P 5 .09 and P 5 .11, respectively; Supporting Fig. 5A [see online supporting information]). Most TP53 mutations were missense mutations (n 5 61; median OS, 19.3 months), and patients with such mutations had improved OS in comparison with patients without TP53 mutations detected by the CMS50 panel (P 5 .002). In contrast, the presence of a truncating mutation in TP53 was less common (n 5 21) and was not associated with a significant difference in survival from stage IV (median OS, 12.9 months; P 5 .93; Supporting Twenty-seven different BRAF Non-V600 mutations were detected in a total of 60 patients in the cohort (Supporting Table 5 [see online supporting information]). BRAF Non-V600 mutations were detected in 2 patients with BRAF V600 mutations (0.5%), in 8 patients with NRAS mutations (4.1%), and in 50 patients with neither BRAF V600 nor NRAS mutations (14.9%; Supporting Fig. 1B [see online supporting information]). In the full cohort, the presence of a BRAF Non-V600 mutation (6.5%) was associated with a significantly older age at diagnosis (median, 60 vs 56 y; P 5 .005; Table 3 ). No other significant correlations with patient demographics or primary tumor characteristics were identified. Among the 531 patients diagnosed with stage IV disease, the presence of a BRAF Non-V600 mutation (n 5 41 or 7.7%) was not associated significantly with the M1 stage or serum LDH levels.
Clinical and pathological characteristics of BRAF Non-V600 mutations were examined separately in melanomas with a concurrent BRAF V600 mutation, in melanomas with a concurrent NRAS mutation, and in melanomas without a BRAF V600 or NRAS mutation (Supporting Table  7 [see online supporting information]). Nonsignificant trends for deeper Breslow thickness with BRAF Non-V600 mutations were observed in tumors without a BRAF V600 or NRAS mutation (P 5 .08), but no statistically significant associations were detected.
BRAF Non-V600 Mutations and OS From Stage IV
A BRAF Non-V600 mutation was detected in 25 of the patients (6.0%) with mutation testing performed within 12 months of the diagnosis of stage IV disease. There was no significant difference in OS from stage IV between patients with (median, 17.9 months) and without a BRAF Non-V600 mutation (median, 16.1 months; P 5 .53); Fig. 1C ). There was no patient with a BRAF V600 mutation who had mutation testing within 12 months of the stage IV diagnosis and had a concurrent BRAF Non-V600 mutation, and there was only 1 among 86 patients with an NRAS mutation. An analysis of patients without a concurrent BRAF V600 or NRAS mutation failed to detect a significant association between OS from stage IV and the BRAF Non-V600 mutation status (P 5 .95; Supporting Twenty-one of the patients (8.9%) treated with ipilimumab had a BRAF Non-V600 mutation. No significant correlation between the BRAF Non-V600 mutation status and OS from the start of ipilimumab treatment was observed (median, 12.5 vs 13.5 months; P 5 .44; Fig. 1D ).
Eleven patients with a BRAF Non-V600 mutation were treated with an FDA-approved BRAF inhibitor (vemurafenib, n 5 9; dabrafenib, n 5 1; dabrafenib plus trametinib, n 5 1). All of the patients had stage 4 disease, and none of the patients had a concurrent BRAF V600 or NRAS mutation (Table 4) . Three patients treated with vemurafenib were not evaluable for a response because of early severe drug-related toxicities; the remaining 8 patients had disease progression as their best response to therapy. The median PFS and OS were 1.9 months (95% confidence interval [CI], 1.48-2.32 months) and 7.1 months (95% CI, 4.54-9.66 months), respectively (Supporting Fig.  7A ,B [see online supporting information]). Because BRAF K601 and L597 mutations are located in the activating kinase domain of BRAF and a BRAF inhibitor demonstrated some antitumor activity in a patient with a BRAF L597-mutant melanoma, 13 clinical outcomes of patients with BRAF K601 and L597 mutations were compared with the other BRAF Non-V600 mutations after BRAF inhibitor treatment. There were no differences in PFS and OS between patients with BRAF K601 and L597 mutations and patients with the other BRAF Non-V600 mutations (Supporting Fig. 7C,D BRAF Non-V600 mutations (BRAF L597R, G466E, and G469E) treated with trametinib (MEK inhibitor) monotherapy (Table 4) .
Multivariate Analysis
Multivariate Cox regression modeling was performed to identify significant predictors of OS from the stage IV diagnosis, including sex, M1 stage, LDH, and the BRAF V600 , NRAS, TP53, and BRAF Non-V600 mutation status (Table 5 ). Age and the presence of stage IV M1c disease were associated with a nonsignificant trend of shorter OS from stage IV (P 5 .05 and P 5 .08). The presence of a TP53 mutation was associated with improved OS from stage IV (hazard ratio, 0.62; 95% CI, 0.42-0.91; P 5 .015).
DISCUSSION
A number of previous studies have described the clinical and pathological features associated with BRAF V600 and NRAS mutations, 3, 14, 15 which are the most common hotspot oncogenic mutations detected in cutaneous melanomas. Although many other mutations have been identified in melanoma, the ability to assess their clinical associations has been limited by their relative scarcity. In this study, we have used a retrospective cohort of 926 non-acral cutaneous melanoma patients who underwent clinically indicated NGS testing to expand the integrated analysis of molecular and clinical features in this disease. This analysis focused on TP53 and BRAF Non-V600 mutations because they are particularly common in cutaneous melanomas without BRAF V600 or NRAS mutations and because preclinical data support potential functional roles for both events in this disease.
TP53 encodes a tumor-suppressor gene that is altered in many cancer types. We identified TP53 mutations in 19% of the full cohort of cutaneous melanoma patients who had undergone molecular testing with the clinical CMS50 NGS panel; this was similar to the rate observed in TCGA for melanoma (15%).
11 In comparison with patients who did not have an alteration detected by this panel, TP53 mutations were associated with older age and an increased rate of head and neck primary tumor sites. These clinical associations are consistent with the observed correlation between UVRinduced DNA damage and TP53 mutations in cutaneous melanoma. 16, 17 In this cohort, 58% of TP53 mutations were consistent with ultraviolet-induced DNA damage, and this is again similar to the rate reported in TCGA for melanoma (45.3%). 11 Although preclinical studies have shown that TP53 mutations accelerate BRAF V600 -driven melanomagenesis, 17, 18 we observed that TP53 mutations were associated with significantly improved survival from the diagnosis of stage IV disease in univariate and multivariate analyses. The observed association of improved outcomes for patients with melanomas with TP53 mutations contrasts with associations with poor clinical outcomes in a number of other cancers, including breast cancer, 19 head and neck cancer, 4 and hematologic malignancies. 5 However, these results are consistent with a previous study that identified improved clinical outcomes for patients with melanomas with overexpression of the P53 protein, 20 which is usually associated with mutations in the TP53 gene. Our analysis also showed that missense substitution mutations in TP53, mutations that affected the DNAbinding domain of the P53 protein, and high-risk evolutionary scores for TP53 mutations were associated with significant improvements in OS from stage IV, but truncating mutations, mutations affecting other domains, and low-risk evolutionary scores were not. Although these findings may further help us to interpret the results of TP53 molecular testing results, the analysis of truncating mutations, mutations affecting other domains, and low-risk evolutionary scores were limited by the small number of patients with such alterations in this cohort.
At this time, it is unclear why TP53 mutations are associated with improved survival for stage IV melanoma patients. The presence of a somatic mutation in TP53 was also associated with a trend for improved OS from the initial diagnosis in the full melanoma TCGA cohort as patients with a TP53 mutation (n 5 64) had a median OS of 170 months, whereas patients without a TP53 mutation (n 5 350) had a median OS of 114 months (P 5 .44 ). An analysis limited to the TCGA patients with stage III or IV metastases also showed a trend for improved OS with a TP53 mutation (median OS, not reached vs 72.8 months; P 5 .25). Although the observed differences are interesting, the TCGA cohort included stage II to IV melanomas, many tumors were collected after previous recurrences, the date of stage IV disease was unknown for the overwhelming majority of the patients, and there were not sufficient data to evaluate associations with known stage-specific prognostic factors for the cohort. Thus, studies of additional cohorts with appropriate power and annotation will need to be performed in the future to further assess the prognostic significance of TP53 mutations in melanoma. Notably, our analysis of survival was limited to patients with molecular testing performed within 12 months of the stage IV diagnosis to avoid biasing results by the inclusion of patients who survived for a prolonged period of time before undergoing molecular testing; this is another factor to consider in the evaluation of molecular prognostic factors. Recent studies support the idea that an increased missense mutation burden correlates with improved survival in metastatic melanoma patients. 21 Because TP53 mutations are associated with an increased mutation burden (including the melanoma TCGA cohort; P < .0001 by a Mann-Whitney test), it is possible that the presence of this mutation signifies the likelihood of an increased mutation burden and, therefore, enhanced antitumor immune surveillance. Although this is a reasonable hypothesis, we did not observe a significant association between the presence of a TP53 mutation and an improvement in OS with ipilimumab. Because the relatively low response and longterm survival rates for ipilimumab are modest, this analysis was somewhat limited for detecting a positive association. Additional studies may be performed in the future to examine outcomes for patients treated with more active immunotherapy regimens such as anti-programmed death 1 antibodies and adoptive T-cell therapy.
BRAF Non-V600 mutations were detected in 6% of the full cohort of cutaneous melanomas in this study, and this is also consistent with our previous report 2 and TCGA data for melanoma. BRAF Non-V600 mutations were extremely rare in cutaneous melanomas with a concurrent BRAF V600 mutation (0.5%), but they were more frequent in melanomas with an NRAS mutation (4%) and in melanomas with neither of those oncogenic driver mutations (15%). In contrast to the TP53 mutation analysis, there was no significant association observed between BRAF Non-V600 mutations and OS from the stage IV diagnosis or with ipilimumab treatment.
In agreement with previous clinical data, 22, 23 patients with BRAF Non-V600 mutations in this cohort who were treated with FDA-approved BRAF inhibitors had no clinical responses. The failure of a selective BRAF inhibitor in BRAF Non-V600 -mutant melanoma can be explained by preclinical data showing activation of endogenous CRAF in BRAF Non-V600 -mutant melanoma. 6 In contrast to other BRAF Non-V600 mutations, BRAF K601 and L597 mutations are located in the activating domain of BRAF, and a clinical response to a BRAF inhibitor has previously been reported in 1 metastatic melanoma patient with a BRAF L597 mutation. 13 However, we did not observe any clinical responses in this study in patients with a BRAF Non-V600 mutation. Although there is evidence that MEK inhibitors may be an effective strategy for melanomas with BRAF Non-V600 mutations and an objective response to a selective MEK inhibitor was reported in BRAF L597S-mutant melanoma, 6, 24 no responses were seen among 3 patients with BRAF L597R, G466E, or G469E mutations in this cohort who were treated with trametinib. A prospective, open-label, phase 2 study (NCT02296112) is currently being performed to further characterize the safety and activity of trametinib in patients with BRAF Non-V600 mutations and particularly to examine whether clinical activity is enhanced with specific mutations. Notably, the finding that BRAF Non-V600 mutations do not correlate significantly with OS from stage IV or with ipilimumab treatment is beneficial for the interpretation of the clinical results seen in that study.
Because our study was conducted at a single tertiary cancer center, it is possible that different results may be detected in other melanoma patient populations. Indeed, we do note that serum LDH, which is part of the American Joint Committee on Cancer staging system for stage IV melanoma, was not prognostic in the cohort of patients with molecular testing within 12 months of the diagnosis of stage IV disease. The reason for this finding in this cohort is unknown. However, our cohort is quite large and thus likely represents significant clinical heterogeneity that is seen at melanoma centers. Notably, the clinical NGS panel did not perform NGS of the entire encoding region of TP53 or BRAF (Supporting Table 1 [see online supporting information]). Thus, the actual prevalence of TP53 and BRAF Non-V600 mutations could be higher than detected with this clinical panel. However, the observed rates of TP53 and BRAF Non-V600 mutations are very similar to those reported in the initial report of the melanoma TCGA effort, 11 which included whole-exome sequencing. This is likely due to the fact that the regions that were sequenced in the clinical panel were selected on the basis of existing data about the location of common mutations. Indeed, the residues in TP53 that are assessed for mutations in the CMS50 panel largely overlap with the mutations that were detected in TCGA for melanoma (Supporting Fig. 8 [see online supporting information] ). However, we do note the limitation that the clinical CMS50 panel is not optimal to detect medium and long deletions or chromosomal copy number changes which are affecting the TP53 gene. On the basis of our observations, there is a strong rationale for a comprehensive evaluation of the TP53 gene in other cohorts of clinically annotated stage IV melanoma patients.
In conclusion, this study reports an analysis of the largest single-institution cohort of clinically and molecularly characterized advanced cutaneous melanoma patients to date. The size of this cohort has allowed us to examine the clinical and pathological features that are significantly associated with TP53 and BRAF Non-V600 mutations. Our results suggest that in contrast to many other tumor types, TP53 mutations may correlate with a favorable prognosis for advanced cutaneous melanoma patients, at least for those who undergo molecular testing within 12 months of the stage IV diagnosis. In addition, our studies show that BRAF Non-V600 mutations are not prognostic for stage IV melanoma patients, and this information will augment the design and interpretation of current and future clinical trials in this patient population. Further studies including prospective and mechanistic analysis are needed to validate our findings.
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